CAS 15307-86-5|Diclofenac
Introduction：Basic information about CAS 15307-86-5|Diclofenac, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Diclofenac | ||
|---|---|---|---|
| CAS Number | 15307-86-5 | Molecular Weight | 296.149 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 412.0±45.0 °C at 760 mmHg |
| Molecular Formula | C14H11Cl2NO2 | Melting Point | 156-158ºC |
| MSDS | / | Flash Point | 203.0±28.7 °C |
Names
| Name | diclofenac |
|---|---|
| Synonym | More Synonyms |
Diclofenac BiologicalActivity
| Description | Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 nM, 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1, 0.84 μM for ovine COX-1 and COX-2, respectively. |
|---|---|
| Related Catalog | Signaling Pathways >>Immunology/Inflammation >>COXResearch Areas >>Inflammation/Immunology |
| Target | Human COX-2:1.3 nM (IC50, in CHO cells) Human COX-1:4 nM (IC50, in CHO cells) Ovine COX-2:0.84 μM (IC50) Ovine COX-1:5.1 μM (IC50) |
| In Vitro | Diclofenac is a potent COX inhibitor, with IC50s of 4 nM and 1.3 nM for human COX-1 and COX-2 in the CHO cells, respectively. Diclofenac effectively blocks COX-1 mediated prostanoid production from U937 cell microsomes, with an IC50 of 7 ± 3 nM[1]. Diclofenac sodium exihibits inhibition on COX-1 and COX-2 enzyme with IC50s of 5.1 and 0.84 μM, respectively[2]. |
| In Vivo | Diclofenac (3 mg/kg, b.i.d., for 5 days) significantly increases faecal 51Cr excretion in rats, and such effect is also observed in squirrel monkeys after administrated of 1 mg/kg twice daily for 4 days[1]. Diclofenac (10 mg/kg) shows anti-inflammatory activity in mice[2]. Diclofenac (10 mg/kg) decreases oxidized low-densitylipoprotein (Ox-LDL), but shows no effects on the kinetics parameters of catalase and glutathione peroxidase via intramuscularly injection into rats[3]. |
| Animal Admin | Rats[1] Male Sprague-Dawley rats (150 ± 200 g) are dosed orally with Diclofenac either once (acute dosing) or twice daily for 5 days (chronic dosing). A plasma sample is obtained 1 h after the morning dose on day 4 for measurement of Diclofenac concentration. Immediately after the administration of the last dose on day 5, the rats are injected via a tail vein with 0.5 mL of 51Cr-labelled red blood cells from a donor rat after incubation with sodium 51chromate. The rats are placed individually in metabolism cages with food and water ad libitum. Faeces are collected for a 48 h period and 51Cr faecal excretion is calculated as a % of total injected dose (20 mCi per animal)[1]. Squirrel monkeys[1] Squirrel monkeys (Saimiri sciureus; 0.8 ± 1.4 kg) are dosed orally with Diclofenac twice daily for 1 ± 5 days. One hour after administration of the last dose, 51CrCl3 in sterile saline (1 mL/kg, 4 ± 5 mCi per animal) is injected via a saphenous vein and plasma samples are obtained for measurement of Diclofenac concentration. The monkeys are then housed individually in metabolism cages. Faeces are collected for a 24 h period and 51Cr faecal excretion is calculated as a % of total injected dose[1]. |
| References | [1]. Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17. [2]. Labib MB, et al. Design, synthesis of novel isoindoline hybrids as COX-2 inhibitors: Anti-inflammatory, analgesic activities and docking study. Bioorg Chem. 2018 Oct;80:70-80. [3]. Curcelli EC, et al. Beneficial effects of diclofenac therapy on serum lipids, oxidized low-density lipoprotein and antioxidant defenses in rats. Life Sci. 2008 Apr 9;82(15-16):892-8. |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 412.0±45.0 °C at 760 mmHg |
| Melting Point | 156-158ºC |
| Molecular Formula | C14H11Cl2NO2 |
| Molecular Weight | 296.149 |
| Flash Point | 203.0±28.7 °C |
| Exact Mass | 295.016693 |
| PSA | 49.33000 |
| LogP | 4.06 |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.662 |
| InChIKey | DCOPUUMXTXDBNB-UHFFFAOYSA-N |
| SMILES | O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 1070 ug/kg
- TOXIC EFFECTS :
- Skin and Appendages - dermatitis, other (after systemic exposure)
- REFERENCE :
- AIMEAS Annals of Internal Medicine. (American College of Physicians, 4200 Pine St., Philadelphia, PA 19104) V.1- 1927- Volume(issue)/page/year: 117,1058,1992
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 62500 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 170 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- PHARAT Pharmazie. (VEB Verlag Volk und Gesundheit, Neue Gruenstr. 18, Berlin DDR-1020, Ger. Dem. Rep.) V.1- 1946- Volume(issue)/page/year: 37,148,1982
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 345 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 43,44,1993 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 4 mg/kg
- SEX/DURATION :
- female 13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- REFERENCE :
- JCGBDF Journal of Craniofacial Genetics and Developmental Biology. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 10,83,1990
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intramuscular
- DOSE :
- 4 mg/kg
- SEX/DURATION :
- female 13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- REFERENCE :
- JCGBDF Journal of Craniofacial Genetics and Developmental Biology. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 10,83,1990
Safety Information
| Hazard Codes | Xi |
|---|---|
| RIDADR | 3249 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
| HS Code | 2942000000 |
Customs
| HS Code | 2922499990 |
|---|---|
| Summary | HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0% |
Synonyms
| 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid |
| Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)- |
| 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetic acid |
| Acetic acid, (o-(2,6-dichloroanilino)phenyl)- |
| 2-[[2,6-Dichlorophenyl]amino]benzeneacetic acid |
| MFCD00451393 |
| 2-((2,6-dichlorophenyl)amino)benzeneacetic acid |
| Diclofenac acid |
| 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetic acid |
| N-(2,6-Dichlorophenyl)-o-aminophenylacetic Acid |
| Zorvolex |
| EINECS 239-348-5 |
| {2-[(2,6-Dichlorophenyl)amino]phenyl}acetic acid |
| [2-(2,6-dichloroanilino)phenyl]acetic acid |
| Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- |
| Motifene |
| (o-(2,6-Dichloroanilino)phenyl)acetic Acid |
